Abstract: A method for reducing post-ischaemic injury of the heart and/or improving the functional recovery of the heart following myocardial ischaemia which method comprises administration of an effective, non-toxic amount of a glucose uptake enhancer to a human or non-human mammal in need thereof.
Abstract: The present invention relates to a novel pharmaceutical composition and process for preparing swallowable rapidly disintegrating methylcellulose and lipstatin derivatives together in combination with a suitable diluent and excipients.
Abstract: This invention relates to novel compounds of Formula (I) to (VII), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
Abstract: NK3 receptor antagonists of formula (I):
in which:
Ar is an optionally substituted phenyl group, or a naphthyl or C5-7 cycloalkdienyl group, or an optionally substituted single or fused ring heterocyclic group, having aromatic character, containing from 5 to 12 ring atoms and comprising up to four hetero-atoms in the or each ring selected from S, O, N;
R is linear or branched C1-8 alkyl, C3-7 cycloalkyl, C4-7 cycloalkylalkyl, an optionally substituted phenyl group or a phenyl C1-6 alkyl group, an optionally substituted five-membered heteroaromatic ring comprising up to four heteroatoms selected from O and N, hydroxy C1-6 alkyl, amino C1-6 alkyl, C1-6 alkylaminoalkyl, di C1-6 alkylaminoalkyl, C1-6 acylaminoalkyl, C1-6 alkoxyalkyl, C1-6 alkylcarbonyl, carboxy, C1-6 alkoxyxcarbonyl, C1-6 alkoxycarbonyl C1-6 alkyl, aminocarbonyl, C1-6 alkylaminocarbonyl, di C1-6 alkylaminocarbonyl, halogeno C1-6 alkyl; or is a group —(CH2)p— when cyclized onto Ar, where p is 2 or 3;
R1 and R2, whi
Type:
Grant
Filed:
May 25, 1995
Date of Patent:
August 19, 2003
Assignee:
SmithKline Beecham Farmaceutici S.p.A
Inventors:
Carlo Farina, Giuseppe Arnaldo Maria Giardina, Mario Grugni, Luca Francesco Raveglia
Abstract: Piperidine derivatives and pharmaceutical derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly in man.
Type:
Grant
Filed:
May 24, 2001
Date of Patent:
August 5, 2003
Assignee:
SmithKline Beecham p.l.c.
Inventors:
David Thomas Davies, Roger Edward Markwell, Neil David Pearson, Andrew Kenneth Takle
Abstract:
Compounds of formula (I) in which: R1 is hydrogen or an organic substituent group; R2 is a fused bicyclic heterocyclic ring system of general formula (a) wherein R4 and R5 are independently hydrogen or one or more substituents replacing hydrogen atoms in the ring system shown; m is 2 or 3; p is 0, 1 or 2; and R3 is hydrogen, a salt-forming cation or an ester-forming group; and the symbol ═/═ indicates that the double bond may be in either the E or Z configuration.
Type:
Grant
Filed:
May 24, 1995
Date of Patent:
July 29, 2003
Assignee:
SMithKline Beecham p.l.c.
Inventors:
Nigel John Perryman Broom, Frank Peter Harrington
Abstract: Compounds of formula (I):
in which:
one of X and Y is N and the other is CH;
Z represents oxygen or sulfur;
and R1 to R7 represent various substituent groups;
and pharmaceutically acceptable salts thereof.
Type:
Grant
Filed:
December 5, 2001
Date of Patent:
July 22, 2003
Assignee:
SmithKline Beecham p.l.c.
Inventors:
Steven Coulton, Amanda Johns, Roderick Alan Porter
Abstract: This invention relates to the compound of Formula (I): or a pharmaceutically acceptable salt, hydrate or solvate thereof, which is an inhibitor of cysteine proteases, particularly cathepsin K, and is useful in the treatment of diseases in which inhibition of bone loss or of cartilage degradation is a factor.
Type:
Grant
Filed:
May 6, 2002
Date of Patent:
July 22, 2003
Assignee:
SmithKline Beecham Corporation
Inventors:
Robert W. Marquis, Jr., Daniel Frank Veber
Abstract:
A process for preparing compounds of formula (I), by nitrosating compounds of formula (II), compounds of formula (I) having pharmaceutical activity.
Abstract: The invention provides Defl polypeptides and DNA (RNA) encoding Defl polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing Defl polypeptides to screen for antibacterial compounds.
Type:
Grant
Filed:
August 15, 1997
Date of Patent:
July 1, 2003
Assignee:
SmithKline Beecham Corporation
Inventors:
Michael Arthur Lonetto, Richard Lloyd Warren, Daniel Robert Sylvester
Abstract: The present invention provides compounds which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.
Abstract: This invention relates to the compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or solvent thereof, which is an inhibitor of cysteine proteases, particularly cathespin K, and is useful in the treatment of diseases in which inhibition of bone loss or of cartilage degradation is a factor
Type:
Grant
Filed:
May 6, 2002
Date of Patent:
June 24, 2003
Assignee:
SmithKline Beecham Corporation
Inventors:
Robert Wells Marquis, Jr., Daniel Frank Veber
Abstract: A process for the preparation of methyl 2-(3-chloropropoxy)-indole-3-carboxylate, which comprises reacting a 3-chloro-3-carboxylate indole compound with 3-chloropropanol in the presence of an acid having a pKa of from 0 to 2.
Abstract: The present invention relates generally to compositions comprising potentiators, such as IL-18, also known as interferon-&ggr;-inducing factor (IGIF), in combination with a chemotherapeutic agent, processes for making such compositions, the use of such compositions for the prevention and/or treatment of cancer, and the use of such compositions to inhibit the growth of tumors or cancerous cells in mammals.